Choosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
|
|
- Prudence West
- 6 years ago
- Views:
Transcription
1 Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent
2 What is the golden standard in premenopausal hormonal sensitive early breast cancer?
3 Ovarian Suppression alone 5 years Tamoxifen OS + AI Tamoxifen followed by AI OS + Tam CT followed by +/- LHRH-a +/- Tam Ovarian protection with LHRH-a
4 Ovarian Suppression alone 5 years Tamoxifen OS + AI Tamoxifen followed by AI OS + Tam CT followed by +/- LHRH-a +/- Tam Ovarian protection with LHRH-a
5 How to increase survival? EBCTCG Lancet 2005 Vol 365:
6 15-y follow-up Tamoxifen vs. control Recurrence rates EBCTCG The Lancet 2003
7 15-y follow-up Tamoxifen vs. Control Deaths rates EBCTCG The Lancet 2003
8 Ovarian Suppression + AI High risk patients Contra-indications for Tamoxifen Studies: SOFT TEXT Informed consent Risk for osteoporose 2 to 5 years LHRH-a? When is the patient menopausal?
9 Tamoxifen followed by AI Peri-menopausal woman When is the patient menopausal? What when she starts bleeding again?
10 Ovarian Suppression alone 5 years Tamoxifen OS + AI Tamoxifen followed by AI OS + Tam CT followed by +/- LHRH-a +/- Tam Ovarian protection with LHRH-a
11 What is the golden standard in Postmenopausal hormonal sensitive early breast cancer?
12 UPFRONT SWITCH SEQUENTIAL EXTENDED SUPPOPULATIONS CYP2D6 CONTRA-INDCATIONS FOR TAMOXIFEN More than 5y AI s
13 UPFRONT SWITCH SEQUENTIAL EXTENDED SUBPOPULATIONS CYP2D6 CONTRA-INDCATIONS FOR TAMOXIFEN More than 5y AI s
14 Subgroup analysis 2 types of error Attributing an effect to a subgroup when there is no overall effect Claiming a lack of effect in a subgroup when the overall effect is significant * The more subgroups into which a data set is devided, the more likely it is that a statistically significant difference will be found by chance J. Cuzick: The Breast April 2008
15 Overview trials AI s Randomisation Median follow-up periode Tamoxifen 5y Anastrozole 5y Tamoxifen 5y Letrozole 5y Tam 2y Letro 3y Letro 2y Tam 3y ATAC 100 months BIG months Tam 2-3y Exe 2-3y Placebo Letrozole 5y IES 55.7 months MA years
16 UPFRONT SWITCH SEQUENTIAL EXTENDED SUBPOPULATIONS CYP2D6 CONTRA-INDCATIONS FOR TAMOXIFEN More than 5y AI S
17 Prominent early peak of recurrences 25 Total Tumour size (>3 cm) Node 0 ER +ve 20 Node 1-3 ER -ve Node (4+) Premenopausal Hazard of recurrence by yearly interval Tumour size (<1 cm) Tumour size (1.1-3 cm) Postmenopausal Time (years) ER, oestrogen receptor Saphner T et al. J Clin Oncol 1996 Baum M. ASCO 2005, poster 612
18 Aromatase inhibitors as initial therapy Initial adjuvant trial (ATAC, BIG 1-98) Randomisation Patients Newly Diagnosed 5 years Tamoxifen 5 years Aromatase Inhibitor 0 5 Time (years) AI upfront Background Data ATAC Anastrozole vs Tamoxifen ATAC Anastrozole vs Tamoxifen BIG 1-98 Letrozole vs Tamoxifen FU DFS(HR+ patients) 68 mths HR=0.83 SS 100 mths HR=0.85 SS 51 mths HR=0.82 SS TTR(HR+ patients) HR=0.74 SS HR=0.76 SS HR=0.78 SS TTDR(HR+ patients) HR=0.84 NS HR=0.84 SS HR=0.81 SS OS(HR+ patients) HR=0.97 NS HR=0.97 NS HR=0.91 NS ATAC: Lancet Oncology 2008; 9: ATAC: Lancet 2005; 365: BIG 1-98: Coates AS et al. J Clin Oncol 2007; 25(5)
19 Time to recurrence ATAC HR+ patients Patients (%) HR+ HR % CI (0.67, 0.87) p-value % Tamoxifen (T) Anastrozole (A) 12.5% 17.0% % 0 Absolute difference 2.8% 4.8% Follow-up time (years) The ATAC Trialists Group. Lancet Oncol 2008; 9: 45-53
20 TTR: Carryover effect in post-treatment period Recurrence rates continued to be lower with anastrozole after treatment completion¹ There is a statistically significantly difference in TTR (HR=0.75, 95% CI , p=0.01)¹, which shows a larger carryover effect for anastrozole TTR, time to recurrence ¹The ATAC Trialists Group. Lancet Oncol 2008; 9: 45-53
21 BIG1-98 Treatment arm of 5 years Tamoxifen is unblinded (June 2005) New methode of statistical analysis was proposed on ESMO Sept 2008 and data will be present in San Antonio 2008
22 Switching Analysis [TAM LET] vs TAM [LET TAM] vs LET 5 Prospective Additional Sequence analysis [TAM LET] vs LET [TAM LET] vs TAM [LET TAM] vs LET [LET TAM] vs TAM [TAM LET] vs [LET TAM] Ref. BIG 1-98, Poster at ESMO 09/2008
23 UPFRONT SWITCH SEQUENTIAL EXTENDED SUBPOPULATIONS CYP2D6 CONTRA-INDCATIONS FOR TAMOXIFEN More than 5y AI s
24 Aromatase Inhibitors: After 2-3 y Tamoxifen Randomisation Switch trial (ITA, ARNO/ABCSG 8, IES) 2-3 years prior Tamoxifen 3-2 y Tamoxifen 3-2 y Aromatase Inh 0 5 Time (years) ARNO Anastrozole vs Tamoxifen ARNO/ABCSG8 Anastrozole vs Tamoxifen ARNO/ABCSG8/ITA Anastrozole vs tam FU DFS OS 30.1 mths HR=0.66 SS 28 mths HR=0.60 SS 30 mths HR=0.59 SS HR=0.53 SS ND HR=0.71 SS IES Exemestane vs tam 55.7 mths HR=0.76 SS HR=0.85 for ITT pts NS HR=0.83 for ER+/unknown pts SS ARNO: Kaufmann M et al. J Clin Oncol 2007; 25(19) - ARNO/ABCSG 8:Jakesz R et al. Lancet Oncology 2005; 366: ARNO/ABCSG 8/ITA: Jonat W et al. Lancet Oncology 2006; 7: IES: Coombes RC et al. Lancet Feb 2007
25 DFS (%) DFS (%) IES-trial: Exemestane After Tamoxifen: DFS Year Abs diff, % (95% CI) Intent to treat End of treatment HR: 0.76 (95% CI: ) Log rank test: P = ( ) E = 354/2352 T = 454/ Time Since Randomization (Yrs) ( ) ( ) Reprinted from The Lancet Oncology, 2006;7: , Jonat W, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a metaanalysis. Copyright (2008), with permission from Elsevier. ER+/Unknown End of treatment HR: 0.75 (95% CI: ) Log rank test: P =.0001 E = 339/2296 T = 438/ Time Since Randomization (Yrs) ( ) Exemestane Tamoxifen
26 Survival in the switch strategy Update on IES: DFS subgroup analysis The size of benefit in DFS for switching to exemestane is consistent across subgroups Coombes R. et al., The Lancet, 2007, vol 369, Issue 9561,
27 UPFRONT SWITCH SEQUENTIAL EXTENDED SUBPOPULATIONS CYP2D6 CONTRA-INDCATIONS FOR TAMOXIFEN More than 5y AI S
28 Aromatase Inhibitors: After 5 y Tamoxifen Randomisation Extended adjuvant trial (MA17, ABCSG 6a, NSABP33) MA 17* Letrozole vs placebo ABCSG 6a Anastrozole vs no treatment 5 years prior tamoxifen 0 5 Time (years) FU DFS DDFS OS 30 mths HR=0.58 SS 60.4 mths HR=0.64 SS HR=0.61 SS Aromatase Inhibitor No treatment HR=0.82 NS HR=0.61 for Node + SS ND NSABP 33** Exemestane vs placebo 30 mths HR=0.68 NS ND *Early unblinded trial **Trial closed prematurely MA 17: Goss PE SABCS 2005 presentation ABCSG 6a: Jakesz R ASCO 2005 Poster 526 NSABP 33: Mamounas E SABCS 2006 Abstr 48
29 Node- Positive Patients Extended Adjuvant Therapy: Letrozole After 5 Years of HR: 0.61* ( ) Tamoxifen MA.17 HR: 0.53* ( ) HR: 0.61* ( ) DFS Distant DFS OS Node- Negative Patients HR: 0.45* ( ) Median follow-up 2.4 years HR: 0.63 ( ) HR: 1.52 ( ) *Statistically significant benefit of letrozole. A similar reduction in local recurrences, new primaries, and distant recurrences occurred in node-positive and node-negative patients Goss PE, et al. J Natl Cancer Inst. 2005;17:
30 Can we identify a superior AI or AI adjuvant strategy? ATAC and BIG1-98 have demonstrated the superiority of AI over TAM in reducing the recurrence risk in the adjuvant setting IES, ABCSG8, ARNO 95 and ITA demonstrated that the switch from TAM to AI after 2-3 years treatment is more effective than continuing TAM for 5 years The different studies can not be directly compared to one another because of the different study groups different definitions of the endpoints
31 Can we identify a superior AI or AI adjuvant strategy? The side effects of the three different AI s seem to be equivalent There appear to be no difference in side effects whether the AI s are used in upfront or in a switch strategy In the switch strategy, the patient population is selected for good respons to endocrine therapy
32 Considering the the high rate of early recurrences, especially early distant metastases, the use of the strongest availlable therapy, in order to reduce most effectively the early relapse risk is certainly warranted
33 UPFRONT SWITCH SEQUENTIAL EXTENDED SUBPOPULATIONS CYP2D6 CONTRA-INDCATIONS FOR TAMOXIFEN More than 5y AI s
34 Additional information FRAGRANCE trial Genomics could be the key to identify women who are particulary endocrine sensitive and who will benefit most from an AI rather than from tamoxifen l
35 What do we know Take home massages (1) Premenopausal: Tamoxifen 5 years LHRH-a as ovarian protection in study or informed consent Verify the menopausal status carefully before starting an AI Ovarian suppression is still an option
36 Take home massages (2) Postmenopausal: Upfront 5y with Anastrozole or letrozole is the only proven treatment strategy for new diagnosed patients that shows an advantages in TTR DFS CLBC TTDR versus 5y Tamoxifen in long follow-up Patient already on Tamoxifen should be switched at the earliest opportunity to an AI. Here the best option is exemestane Patient after 5 years Tamoxifen should switch to letrozole if high risk of recurrence
37 What will we probably know: not know in near future Is a sequence therapy of Tamoxifen followed by Exemestane better than 5 years Exemestane? Open trial TEAM (San Antonio 2008) Is a sequence therapy better than 5 year Letrozole? BIG1-98 (modified protocol San Antonio 2008) Are there differences between the AI s? FACE MA 27 Is longer therapy with a AI better than 5 years? Differents trials ongoing
38
ATAC Trial. 10 year median follow-up data. Approval Code: AZT-ARIM-10005
ATAC Trial 10 year median follow-up data Approval Code: AZT-ARIM-10005 Background FDA post-approval commitment analysis to update DFS, TTR, OS and Safety Prof. Jack Cuzick on behalf of ATAC/LATTE Trialists
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2011 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & Chair NR Committee
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationShould premenopausal HR+ve breast cancer receive LHRH?
Should premenopausal HR+ve breast cancer receive LHRH? Hesham Elghazaly, MD Prof. Clinical Oncology, Ain Shams University President of the BGICS Should premenopausal HR+ve breast cancer receive LHRH? NO?
More informationTerapia Hormonal da Paciente Premenopausa
I Congresso de Oncologia D Or 5 e 6 de julho de 2013 Terapia Hormonal da Paciente Premenopausa Antonio C. Wolff, MD, FACP, FASCO Professor de Oncologia Programa de Câncer de Mama Johns Hopkins University
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 1-year analysis of the ATAC trial Jack Cuzick, Ivana Sestak, Michael Baum, Aman Buzdar, Anthony Howell, Mitch Dowsett,
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationEndocrine Therapy for Early Breast Cancer: Updated Review
REVIEWS AND CONTEMPORARY UPDATES Ochsner Journal 17:405 411, 2017 Ó Academic Division of Ochsner Clinic Foundation Endocrine Therapy for Early Breast Cancer: Updated Review Alexander Tremont, DO, 1 Jonathan
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationThe worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials
The worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials Richard Gray, for the Early Breast Cancer Trialists Collaborative Group (EBCTCG) Main questions, 2005-6 1) 5 years of
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationThe Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer
The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer Erin Roesch, MD, and Claudine Isaacs, MD Abstract Endocrine therapy in the adjuvant setting
More informationStart strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer
Available online at www.sciencedirect.com Biomedicine & Pharmacotherapy 63 (2009) 1e10 Short review Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29317 holds various files of this Leiden University dissertation. Author: Nes, Johanna Gerarda Hendrica van Title: Clinical aspects of endocrine therapy
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More information1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical
1 2 1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationAn updated review on the efficacy of adjuvant endocrine therapies in hormone receptor positive early breast cancer
MEDICAL ONCOLOGY An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor positive early breast cancer S. Verma m d,* S. Sehdev, A. Joy m d, Y. Madarnas m d, J. Younus m d,
More informationEndocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment
Review Article Page 1 of 12 Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment Jun-Jie Li, Zhi-Min Shao Department of
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationScottish Medicines Consortium
Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive
More informationAdjuvant treatment for early breast cancer
Annals of Oncology 16 (Supplement 2): ii182 ii187, 2005 doi:10.1093/annonc/mdi709 Adjuvant treatment for early breast cancer I. Smith The Royal Marsden Hospital, London, UK Introduction Survival rates
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 3 JANUARY 2 2 JOURNAL OF CLINICAL ONCOLOGY S P E C I A L A R T I C L E From the Academic Department of Biochemistry, Royal Marsden Hospital; Cancer Research UK Centre for Epidemiology,
More informationAdjuvant Hormonal Therapy in Peri- and Postmenopausal. Breast Cancer
Breast Cancer Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer Paula D. Ryan, Paul E. Goss Massachusetts General Hospital, Boston, Massachusetts, USA Key Words. Breast cancer Aromatase
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients www.agoonline.de
More informationShould aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
British Journal of Cancer (26) 94, 46 464 & 26 Cancer Research UK All rights reserved 7 92/6 $3. www.bjcancer.com Minireview Should aromatase inhibitors be used as initial adjuvant treatment or sequenced
More informationThe first randomized clinical trial of adjuvant
ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER Aman U. Buzdar, MD* ABSTRACT The safety and efficacy of tamoxifen as adjuvant endocrine therapy for postmenopausal patients
More informationPublished Ahead of Print on July 12, 2010 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on July 12, 2010 as 10.1200/JCO.2009.26.3756 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2009.26.3756 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Hormonal therapies for the adjuvant treatment of early oestrogen-receptor positive breast cancer The overview is written by members of the
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationA review of adjuvant hormonal therapy in
REVIEW Endocrine-Related Cancer (2004) 11 391 406 A review of adjuvant hormonal therapy in breast cancer Kellie L Jones and Aman U Buzdar 1 Department of Pharmacy, University of Texas M.D. Anderson Cancer
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationAdvances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD
Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:
More informationКой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго?
Кой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго? д-р Красимир Койнов МБАЛ Сердика, София Декларация Консултации и хонорари: Roche, Boerhinger Ingelheim, Astra
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationRecent advances in adjuvant systemic treatment for breast cancer: all systems go!
REVIEW ARTICLE Recent advances in adjuvant systemic treatment for breast cancer: all systems go! P.N. Fishman MD* and S. Verma MD MSEd* KEY WORDS Breast cancer, adjuvant, treatment 1. INTRODUCTION Breast
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationSan Antonio Breast Cancer Symposium 2013
15 th Annual Advances in Oncology Navigating Breast Cancer Therapeutics: Early and Late Stage Disease Scott Christensen, MD Professor, Hematology/Oncology UC Davis Comprehensive Cancer Center 15th Annual
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationBreast Cancer Prevention
Prevention 1 In the NSABP-P-1 and IBIS-1 trials, chemoprevention with tamoxifen was found to reduce the incidence of breast cancer in women at higher risk. The ATAC adjuvant trial demonstrated a further
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationThe Oncotype DX Assay A Genomic Approach to Breast Cancer
The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast
More informationNIH Public Access Author Manuscript Nat Rev Clin Oncol. Author manuscript; available in PMC 2012 December 10.
NIH Public Access Author Manuscript Published in final edited form as: Nat Rev Clin Oncol. ; 9(4): 223 229. doi:10.1038/nrclinonc.2012.21. Use of neoadjuvant data to design adjuvant endocrine therapy trials
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationThe HERA Study Team. Presented by Ian E. Smith
Trastuzumab Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer (HERA Trial): Disease-Free and Overall Survival after 2 Year Median Follow-Up The HERA Study Team Presented by Ian E. Smith
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationOsteoporosis management in cancer patients
Osteoporosis management in cancer patients Belgian Menopause Society - Osteoporosis - Brussels, Oct 2017 Prof. JJ Body CHU Brugmann Univ. Libre de Bruxelles Brussels Bone loss associated with hormone ablation
More informationLate Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier. Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program
Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program Conflicts of Interest Research Funding Menarini/Silicon Biosystems(Manufacturer
More informationGiuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups
Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationNuove strategie nella chemioprevenzione e nella terapia ormonale del carcinoma mammario
University of L Aquila Nuove strategie nella chemioprevenzione e nella terapia ormonale del carcinoma mammario Paolo Marchetti Issues of chemoprevention A New Way to Treat Cancer Before It Happens Prevention:
More informationAdjuvant therapy in early breast cancer
Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Centro di Riferimento Regionale per la diagnosi e la terapia dei tumori del colon-retto. D.A. 26/10/2012 G.U.R.S. del 14/12/2012 parte I,
More information